CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...
Brokers Issue Forecasts for CRSP FY2024 Earnings
Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $85.00 at Bank of America
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...
STAT3d
Scribe Therapeutics becomes latest CRISPR company to announce layoffs
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
Check Out What Whales Are Doing With CRSP
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...
Crispr Therapeutics price target lowered to $85 from $98 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.
Business Insider5d
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Nasdaq4d
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
CRISPR Therapeutics AG (CRSP) ended the recent trading session at $41.92, demonstrating a -1.2% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered ...